{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:48:59Z","timestamp":1784634539431,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 HL-007891"],"award-info":[{"award-number":["T32 HL-007891"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P30-ES013508"],"award-info":[{"award-number":["P30-ES013508"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010891","name":"Portola Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jtocrr.2021.100188","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T14:43:51Z","timestamp":1621349031000},"page":"100188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"2","author":[{"given":"Roger Y.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Bagley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina E.","family":"Marmarelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Rendle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3871-8697","authenticated-orcid":false,"given":"Anil","family":"Vachani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2021.100188_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtocrr.2021.100188_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/s-0039-1693406","article-title":"Malignant mesothelioma: has anything changed?","volume":"40","author":"Kim","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jtocrr.2021.100188_bib3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtocrr.2021.100188_bib4","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","article-title":"British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma","volume":"73","author":"Woolhouse","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jtocrr.2021.100188_bib5","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2021.100188_bib8","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtocrr.2021.100188_bib11","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib14","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib15","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical\u2013pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2021.100188_bib17","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1200\/JOP.2014.001354","article-title":"Prevalence of off-label use of oral oncolytics at a community cancer center","volume":"11","author":"Kalis","year":"2015","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.jtocrr.2021.100188_bib18","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1200\/JCO.2012.42.7252","article-title":"Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists","volume":"31","author":"Conti","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-019-0613-x","article-title":"Use of immune checkpoint inhibitors in mesothelioma","volume":"20","author":"Forde","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2217\/fon-2015-0043","article-title":"Opportunities and challenges in leveraging electronic health record data in oncology","volume":"12","author":"Berger","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib22","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1200\/JOP.2017.024224","article-title":"Use of electronic health record data for quality reporting","volume":"13","author":"Abernethy","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.jtocrr.2021.100188_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib25","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1634\/theoncologist.2017-0673","article-title":"Disparities in the use of programmed death 1 immune checkpoint inhibitors","volume":"23","author":"O\u2019Connor","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jtocrr.2021.100188_bib26","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cncr.23228","article-title":"Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002?","volume":"112","author":"Gross","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2021.100188_bib27","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/j.cllc.2020.05.021","article-title":"Gender-based disparities in receipt of care and survival in malignant pleural mesothelioma","volume":"21","author":"Barsky","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2021.100188_bib28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.jtocrr.2021.100188_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jtocrr.2021.100188_bib30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1001\/jama.297.4.403","article-title":"Practice-based research--\u201dBlue Highways\u201d on the NIH roadmap","volume":"297","author":"Westfall","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jtocrr.2021.100188_bib31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","article-title":"The answer is 17 years, what is the question: understanding time lags in translational research","volume":"104","author":"Morris","year":"2011","journal-title":"J\u00a0R Soc Med"},{"key":"10.1016\/j.jtocrr.2021.100188_bib32","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.289.15.1969","article-title":"Disseminating innovations in health care","volume":"289","author":"Berwick","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jtocrr.2021.100188_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.publhealth.031308.100049","article-title":"Diffusion theory and knowledge dissemination, utilization, and integration in public health","volume":"30","author":"Green","year":"2009","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.jtocrr.2021.100188_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0798","article-title":"Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials","volume":"4","author":"O\u2019Connor","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/jnci\/djj115","article-title":"What\u2019s the rush? The dissemination and adoption of preliminary research results","volume":"98","author":"Woloshin","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtocrr.2021.100188_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1503\/cjs.019112","article-title":"Uptake of an innovation in surgery: observations from the cluster-randomized quality initiative in rectal cancer trial","volume":"56","author":"Simunovic","year":"2013","journal-title":"Can J Surg"},{"key":"10.1016\/j.jtocrr.2021.100188_bib37","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jama.2019.10650","article-title":"Association between FDA label restriction and immunotherapy and chemotherapy use in bladder cancer","volume":"322","author":"Parikh","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jtocrr.2021.100188_bib38","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005\u20132012","volume":"311","author":"Downing","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jtocrr.2021.100188_bib39","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1001\/jama.2011.769","article-title":"Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer","volume":"305","author":"Kesselheim","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jtocrr.2021.100188_bib40","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jamaoncol.2016.3337","article-title":"The trade-off between speed and safety in drug approvals","volume":"3","author":"Jena","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtocrr.2021.100188_bib42","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl","key":"10.1016\/j.jtocrr.2021.100188_bib43","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jtho.2021.01.323","article-title":"PS01.11 nivolumab versus placebo in relapsed malignant mesothelioma: the CONFIRM phase 3 trial","volume":"16","author":"Fennell","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib44","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A\u00a0multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2021.100188_bib45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2014.08.017","article-title":"Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials","volume":"86","author":"Mansfield","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2021.100188_bib46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.lungcan.2020.03.024","article-title":"Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - a decision-making analysis amongst European lung cancer experts","volume":"146","author":"Fr\u00fch","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2021.100188_bib47","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1016\/j.cllc.2020.04.006","article-title":"The role of performance status in small-cell lung cancer in the era of immune checkpoint inhibitors","volume":"21","author":"Friedlaender","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2021.100188_bib48","doi-asserted-by":"crossref","first-page":"102031","DOI":"10.1016\/j.ctrv.2020.102031","article-title":"Real world data in the era of Immune Checkpoint Inhibitors (ICIs): increasing evidence and future applications in lung cancer","volume":"87","author":"Pasello","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtocrr.2021.100188_bib49","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtocrr.2021.100188_bib50","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web site and R package for computing E-values","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364321000473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364321000473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:36:09Z","timestamp":1762986969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364321000473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2666364321000473"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100188","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100188"}}